Rasio utang jangka dawa marang modal cero.bio (CERO)

The price trend reflected below serves as an indicator for CERo Therapeutics (CERO), which combines the proprietary CER-T system with high scientific authority to create breakthrough treatments. The current metric is 0.00. Business efficiency is based on the use of automated bioreactors, which minimizes human error and ensures rapid growth in drug production volumes.

The stability of CERo Therapeutics (CERO) in the face of market volatility is determined by its financing structure. The development of innovative T-cell therapy against leukemia requires significant capital expenditures. By analyzing the ratio of long-term liabilities to equity on GURU.Markets, an investor assesses the proportion of loans with maturities exceeding one year relative to equity. This metric reveals the business's dependence on borrowed funds. A low debt load confirms the company's financial autonomy ahead of a potential acquisition by a Big Pharma behemoth.